ROLE OF ICOS IN T CELL RESPONSES AND ANTI-TUMOR IMMUNITY
ICOS 在 T 细胞反应和抗肿瘤免疫中的作用
基本信息
- 批准号:6624705
- 负责人:
- 金额:$ 23.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-12-13 至 2004-11-30
- 项目状态:已结题
- 来源:
- 关键词:CD28 molecule T cell receptor T lymphocyte antigen presenting cell antineoplastics biological signal transduction cell differentiation cell proliferation chimeric proteins disease /disorder model gene expression gene interaction helper T lymphocyte immunoregulation immunosuppression interleukin 10 interleukin 4 laboratory mouse laboratory rat leukocyte activation /transformation monoclonal antibody neoplasm /cancer genetics neoplasm /cancer immunology phosphatidylinositol 3 kinase receptor expression
项目摘要
The BY-CD28/CTLA-4 co-stimulatory pathway has a critical role in regulating T cell activation, and manipulation of this key immunoregulatory pathway has great therapeutic potential. We have cloned a novel murine gene that is a third member of the CD28/CTLA4 gene family and is the murine homologue of the recently described human ICOS (Inducible Co-stimulatory) gene. ICOS is expressed on activated murine T cells and expression as restricted to T cells, similarly to CD28 and CTLA4. In humans, ICOS functions as a receptor for co-stimulatory signals leading to T cell proliferation and production of IL-4 and IL-10, but not IL-2. The relationships of ICOS with the receptors and ligands in the B7-CD28/CTLA-4 pathway need to be define. It is not yet known whether ICOS binds B7 co-stimulators or if ICOS binds to an as yet to be identified counter-receptor in a parallel pathway. It is also not clear when ICOS co-stimulation is needed during immune response. Because ICOS stimulates IL-4 and super-induces IL-10 production, ICOS co-stimulation may have an important role in T cell differentiation and the generation of regulatory T cells. Therefore, manipulation of ICOS signaling may have therapeutic potential. The goal of this research project is to elucidate the role of ICOS co-stimulation in T cell activation, differentiation, and tumor immunity. We have developed a murine ICOS fusion protein that enables us to analyze the function of ICOS on naive and previously activated T cells to characterize the expression and function of ICOS counter-receptor, and to analyze the function of ICOS interactions with the B7/CD28 pathway. In this project, we will characterize how ICOS functions as a receptor for co-stimulator signals from antigen presenting cells and how ICOS regulates T cell proliferation and differentiation. We will examine the role of ICOS co-stimulation in the generation of an effective anti-tumor response in vivo using the EL4 tumor model since the role of IL-4 and IL-10 in suppression of effective tumor immunity has been well defined in this model. ICOS function may deviate the immune response away from a protective cytolytic anti-tumor response and towards a suppressive anti-tumor Th2 response. To understand the role of ICOS in the T cell response and in anti-tumor immunity, I propose to: SPECIFIC AIM 1. To examine the role of ICOS in T cell activation and differentiations. SPECIFIC AIM 2. To examine the expression the expression of ICOS counter-receptor on APC and characterize its molecular structure. SPECIFIC AIM 3. To examine how blocking ICOS signals affect the immune response to murine tumors.
BY-CD28/CTLA-4共刺激途径在调节T细胞激活中具有关键作用,并且对该关键免疫调节途径的操纵具有很大的治疗潜力。我们克隆了一个新型的鼠基因,该基因是CD28/CTLA4基因家族的第三个成员,并且是最近描述的人类ICOS(诱导共刺激性)基因的鼠同源物。 ICO在活化的鼠T细胞上表达,并表达为限制于T细胞,类似于CD28和CTLA4。在人类中,ICOS充当共刺激信号的受体,导致T细胞增殖和IL-4和IL-10的产生,而不是IL-2。需要定义ICO与B7-CD28/CTLA-4途径中受体和配体的关系。尚不清楚ICOS是否结合B7共刺激剂或ICOS是否在平行途径中鉴定为尚未识别的反受体。在免疫反应期间需要ICOS共刺激时,还不清楚。由于ICO刺激IL-4和超级诱导IL-10的产生,因此ICOS共刺激可能在T细胞分化和调节T细胞的产生中具有重要作用。因此,对ICOS信号传导的操纵可能具有治疗潜力。该研究项目的目的是阐明ICOS共刺激在T细胞激活,分化和肿瘤免疫力中的作用。我们已经开发了一种鼠ICOS融合蛋白,使我们能够分析ICOS对NAIVE和先前激活的T细胞的功能,以表征ICOS反受体的表达和功能,并分析ICOS与B7/CD28途径的功能。在这个项目中,我们将表征ICOS如何充当来自抗原呈现细胞的共刺激信号的受体以及ICO如何调节T细胞增殖和分化的受体。我们将使用EL4肿瘤模型研究ICOS共刺激在体内生成有效抗肿瘤反应中的作用,因为在该模型中,IL-4和IL-10在抑制有效肿瘤免疫中的作用已得到很好的定义。 ICOS功能可能会使免疫反应偏离保护性细胞溶解抗肿瘤反应,并偏向抑制性抗肿瘤TH2反应。为了了解ICO在T细胞反应和抗肿瘤免疫中的作用,我建议:特定目的1。检查ICOS在T细胞激活和分化中的作用。具体目的2。检查ICOS反感受器在APC上的表达并表征其分子结构。具体目的3。检查阻断ICOS信号如何影响对鼠肿瘤的免疫反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gordon James Freeman其他文献
Gordon James Freeman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gordon James Freeman', 18)}}的其他基金
TIM recognition of phosphatidylserine regulates innate and adaptive immunity
TIM 识别磷脂酰丝氨酸调节先天性和适应性免疫
- 批准号:
8306825 - 财政年份:2003
- 资助金额:
$ 23.75万 - 项目类别:
TIM recognition of phosphatidylserine regulates innate adaptive immunity-Core B
TIM识别磷脂酰丝氨酸调节先天适应性免疫-Core B
- 批准号:
8507125 - 财政年份:2003
- 资助金额:
$ 23.75万 - 项目类别:
TIM recognition of phosphatidylserine regulates innate adaptive immunity-Core B
TIM识别磷脂酰丝氨酸调节先天适应性免疫-Core B
- 批准号:
8831795 - 财政年份:2003
- 资助金额:
$ 23.75万 - 项目类别:
TIM recognition of phosphatidylserine regulates innate and adaptive immunity
TIM 识别磷脂酰丝氨酸调节先天性和适应性免疫
- 批准号:
8676628 - 财政年份:2003
- 资助金额:
$ 23.75万 - 项目类别:
相似国自然基金
鸡T淋巴细胞膜表面BG受体的配体鉴定
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
鸡T淋巴细胞膜表面BG受体的配体鉴定
- 批准号:32102680
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
组织特异性T淋巴细胞调控瓣膜间质细胞受体IL1R1诱导主动脉瓣膜钙化作用机制研究
- 批准号:82000367
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
生物素受体介导细胞毒性T淋巴细胞免疫示踪胶质瘤浸润边界的机制研究
- 批准号:82001886
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
基于PPAR-γ/AMPK/ACC信号通路探讨n-3多不饱和脂肪酸通过调节T细胞转化治疗克罗恩病的作用及机制研究
- 批准号:81900490
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
- 批准号:
10911713 - 财政年份:2023
- 资助金额:
$ 23.75万 - 项目类别:
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics
开发具有单一特异性和改善持久性的细胞治疗产品,以防止对生物治疗药物的免疫
- 批准号:
10726703 - 财政年份:2023
- 资助金额:
$ 23.75万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10530023 - 财政年份:2022
- 资助金额:
$ 23.75万 - 项目类别:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
用于治疗应用的仿生刺激器的工程和测试
- 批准号:
10705808 - 财政年份:2022
- 资助金额:
$ 23.75万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10665769 - 财政年份:2022
- 资助金额:
$ 23.75万 - 项目类别: